Infectious Disease Research Involving PT-141

PT-141 is a substantially modified synthetic derivative of alpha-melanocyte-stimulating hormone. It is also known as Bremelanotide; however, it is more commonly recognized in research articles under the name PT-141. Both male and female hypoactive sexual drive disorder and acute hemorrhage have been the focus of scientific investigations evaluating its efficacy as potential mitigating agent for this condition. Studies suggest that PT-141 is a melanocortin receptor agonist that may act on both the melanocortin-4 and the melanocortin-1 receptors. As suggested by research, it may increase the immune system and increase arousal as reported by certain research studies.

PT-141 Peptide: What is it?

Because the peptide, also known as Bremelanotide, was previously explored in phase IIb research trials for managing female hypoactive sexual desire disorder (HSDD), it is frequently referred to as the female version of Viagra. A melanocortin known as PT-141 may interact largely with the melanocortin 4 receptor (MC-4R) and the MC-1R. In addition, research on PT-141’s potential efficacy in cases of acute bleeding was conducted in 2009. Melanotan 2 (MT-2) is the parent compound from which PT-141, another synthetic melanocortin, was derived.

PT-141 Peptide and Arousal

Findings imply that the peptide PT-141 may potentially activate the MC-4R. This receptor is considered to promote sexual excitement in the central nervous system and to impact sexual behavior. As purported by research conducted on murine models, the act of agonist binding to MC-4R may result in greater levels of arousal and increased rates of copulation in both male and female mice. 

In a clinical trial examining male subjects with erectile dysfunction (ED) who did not react to traditional compounds, researchers purported that around one-third of the male models presented with PT-141 appeared to successfully achieve erection. As the results indicated a significant dose-dependent response, more information is necessary to explore the potential in full range of impact for this peptide. 

PT-141 Peptide and Bleeding

In 2009, researchers made some minor modifications in PT-141 to conduct research on the peptide’s potential within the context of hemorrhagic shock. In hypovolemic (hemorrhagic) shock, researchers considered that through PT-141’s potential to bind to both MC-1R and MC-4R, it may be more effective in preventing ischemia and protecting tissues from an inadequate blood supply. When presented to animal test subjects, the compound appeared to have no significant effects. The name of this modified derivative of PT-141 is PL-6983.

PT-141 Peptide, Viruses and Infections

In a rat model of a particular fungal infection, it was suggested that the MC-1R appeared to have exhibited substantial antifungal and anti-inflammatory potential. This is of utmost significance as existing antifungals are restricted in terms of the mode of action they use, and they all, in some animal test subjects, may create certain effects that are both severe and limiting. The availability of an alternate method for managing fungal infections may have the potential to significantly cut morbidity and death rates, particularly in research models whose immune systems are compromised.

PT-141 Peptide and Cancer

Because the MC-1R receptor is an essential stimulus for DNA repair pathways, it is of vital importance to cancer cell research. As suggested by ongoing studies, models of MC-1R gene variations may be at a higher risk of developing basal and squamous cell carcinoma. Scientists have hypothesized that the altered PT-141 may hold some potential in mitigating the malignancies caused by these mutations, as well as possibly repairing the difficulties these variants may cause.

PT-141 for sale may be found for the highest quality and the most accessible price at Core Peptides. It is important to note that the substances mentioned in this paper have not been approved for human consumption and should not be employed in any bodily introduction. Only licensed professionals, scientists, academics, and researchers are encouraged to seek these products for investigation. These compounds should only be used in controlled environments such as laboratories.

References

[i] M. Sandrock, A. Schulz, C. Merkwitz, T. Schöneberg, K. Spanel-Borowski, and A. Ricken, “Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice,” Reprod. Biol. Endocrinol. RBE, vol. 7, p. 24, Mar. 2009.

[ii] R. C. Rosen, L. E. Diamond, D. C. Earle, A. M. Shadiack, and P. B. Molinoff, “Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra,” Int. J. Impot. Res., vol. 16, no. 2, pp. 135–142, Apr. 2004. [PubMed]

[iii] H. Wessells, V. J. Hruby, J. Hackett, G. Han, P. Balse-Srinivasan, and T. W. Vanderah, “Ac-Nlec[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors,” Neuroscience, vol. 118, no. 3, pp. 755–762, 2003. [PubMed]

[iv] A.-S. Rössler, J. G. Pfaus, H. K. Kia, J. Bernabé, L. Alexandre, and F. Giuliano, “The

melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat,”

Pharmacol. Biochem. Behav., vol. 85, no. 3, pp. 514–521, Nov. 2006. [PubMed]

[v] M. R. Safarinejad and S. Y. Hosseini, “Salvage of sildenafil failures with bremelanotide: a

randomized, double-blind, placebo controlled study,” J. Urol., vol. 179, no. 3, pp. 1066–1071,

Mar. 2008. [PubMed]

[vi] A. H. Clayton et al., “Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial,” Womens Health Lond. Engl., vol. 12, no. 3, pp. 325–337, 2016. [PubMed]

[vi] M. K. Miller, J. R. Smith, J. J. Norman, and A. H. Clayton, “Expert opinion on existing and developing drugs to treat female sexual dysfunction,” Expert Opin. Emerg. Drugs, vol. 23, no. 3, pp. 223–230, 2018. [PubMed]

[vii] “AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to RekyndaTM (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder – AMAG Pharmaceuticals.” . [MarketWatch]

[viii] H. Ji et al., “The Synthetic Melanocortin (CKPV)2 Exerts Anti-Fungal and Anti-Inflammatory Effects against Candida albicans Vaginitis via Inducing Macrophage M2 Polarization,” PloS ONE, vol. 8, no. 2, Feb. 2013. [PLOS ONE]

[ix] V. Maresca, E. Flori, and M. Picardo, “Skin phototype: a new perspective,” Pigment Cell

Melanoma Res., vol. 28, no. 4, pp. 378–389, Jul. 2015. [PubMed]